tirzepatide canada for weight loss Rybelsus, Mounjaro, Wegovy: India's weight-loss drug boom and the risks behind it Weight loss results after 8

(A) n = 2, (B-E) IgG1/A52Su (n=5), IgG1/DA-GIP (n=4), mGIPR-Ab/A52Su (n=6), mGIPR-Ab/DA-GIP (n=6), mGIPR-Ab/P3/A52Su (n=6), mGIPR-Ab/DA-GIP (n=6)

Tirzepatide engages GLP-1 and GIP together, which is why it gets described as a dual agonist

However, some people choose to discontinue treatment when they have reached their goal weight, or for other reasons relating to side effects

The SURPASS trials are designed to evaluate once-weekly tirzepatide doses of 5 mg, 10 mg, and 15 mg with a dose escalation algorithm: starting dose at 2.5 mg weekly for the first 4 weeks, then dose increment of 2.5 mg every 4 weeks until the maintenance dose of 5 mg, 10 mg, or 15 mg is achieved